Pharvaris N.V.
PHVS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | 1.91 | -0.13 | 0.40 |
| FCF Yield | -2.32% | -3.67% | -4.88% | -3.51% |
| EV / EBITDA | -26.73 | -15.34 | -13.19 | -20.23 |
| Quality | ||||
| ROIC | -12.62% | -21.83% | 18.66% | -17.91% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.66 | 0.84 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -2.42% | 22.44% | -10.02% | -4.61% |
| Safety | ||||
| Net Debt / EBITDA | 8.83 | 4.94 | 5.60 | 7.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -4,232.57 |